Ask AI
ProCE Banner Activity

ADCs with Alternative HER2 Targeting Mechanisms and Beyond HER2-Positive Disease: Expanding Potential Benefit to Other Breast Cancer Subsets

Slideset Download

Download this slideset to review the latest data on new directions using antibody drug conjugates in HER2-positive breast cancer and beyond.

Released: October 30, 2020

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by an educational grant from

Daiichi Sankyo, Inc.

Faculty Disclosure

Primary Author

Javier Cortes, MD, PhD

Head, Breast Cancer Program
IOB Institute of Oncology
Madrid and Barcelona, Spain

Javier Cortes, MD, PhD: consultant/advisor: Abbvie, AstraZeneca, Bioasis, Biocon, BioInvent, Biontech, Bliss Biopharmaceutical, Boehringer Ingelheim, BridgeBio, Circle Pharma, Clovis Oncology, Daiichi Sankyo, Delcath Systems, Ellipses, Expres2ion Biotechnologies, GEMoaB, Gilead, Hexagon Bio, Hibercell, Jazz, Leuko, Lilly, Menarini, Merck Sharp & Dohme, Reveal Genomics, Roche, Scorpion Therapeutics, Seattle Genetics, Zymeworks; honoraria: AstraZeneca, Daiichi Sankyo, Eisai, Gilead, Lilly, Merck Sharp & Dohme, Novartis, Pfizer, Roche, Stemline, Zuellig; researcher (paid to institution): Ariad, AstraZeneca, Baxalta/Servier Affaires, Bayer Healthcare, Eisai, F. Hoffmann-La Roche, Guardant Health, Iqvia, Merck Sharp & Dohme, Pfizer, Piqur Therapeutics, Roche; individual publicly traded stock/stock options: Leuko; other financial or material support: AstraZeneca, Daiichi Sankyo, Eisai, Gilead, Merck Sharp & Dohme, Novartis, Pfizer, Roche, Stemline; royalties or patent beneficiary: issued patent: Pharmaceutical Combinations of a PI3K Inhibitor and a Microtubule Destabilizing Agent (WO 2014/199294 A), licensed patent: HER2 as a Predictor of Response to Dual HER2 Blockade in the Absence of Cytotoxic Therapy (US 2019/0338368 A1).